Early decreases in TNFR-1 and TNFR-2 during canagliflozin treatment were independently associated with a lower risk of DKD progression, suggesting that TNFR-1 and TNFR-2 may also serve as potential pharmacodynamic markers of the response to SGLT2is. The gene discussed is TNFRSF1A; the disease is diabetic kidney disease.